Based on the Benitec Biopharma Ltd ADR stock forecast from 3 analysts, the average analyst target price for Benitec Biopharma Ltd ADR is USD 15.20 over the next 12 months. Benitec Biopharma Ltd ADR’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Benitec Biopharma Ltd ADR is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Benitec Biopharma Ltd ADR’s stock price was USD 10.00. Benitec Biopharma Ltd ADR’s stock price has changed by +1.52% over the past week, -8.42% over the past month and +210.56% over the last year.
No recent analyst target price found for Benitec Biopharma Ltd ADR
No recent average analyst rating found for Benitec Biopharma Ltd ADR
Company Overview Benitec Biopharma Ltd ADR
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California. Read Less
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associ...Read More
Frequently Asked Questions About Benitec Biopharma Ltd ADR (BNTC) Stock
Based on ratings from 3 analysts Benitec Biopharma Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on BNTC's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BNTC is USD 15.20 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 13.
BNTC stock's Price/Earning ratio is 51.55.
Our analysis grades BNTC stock's Price / Earning ratio at F. This means that BNTC stock's Price/Earning ratio is above 84% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BNTC may be a overvalued for its sector.
The last closing price of BNTC's stock was USD 10.00.
The most recent market capitalization for BNTC is USD 0.22B.
Based on targets from 3 analysts, the average taret price for BNTC is projected at USD 15.20 over the next 12 months.
This means that BNTC's stock price may go up by +52.00% over the next 12 months.
We can't find any ETFs which contains Benitec Biopharma Ltd ADR's stock.
As per our most recent records Benitec Biopharma Ltd ADR has 16 Employees.
Benitec Biopharma Ltd ADR's registered address is 3940 Trust Way, Hayward, CA, United States, 94545.
You can get more information about it from Benitec Biopharma Ltd ADR's website at https://benitec.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Benitec Biopharma Ltd ADR (BNTC) Stock
Based on ratings from 3 analysts Benitec Biopharma Ltd ADR's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on BNTC's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for BNTC is USD 15.20 over the next 12 months. The maximum analyst target price is USD 17 while the minimum anlayst target price is USD 13.
BNTC stock's Price/Earning ratio is 51.55.
Our analysis grades BNTC stock's Price / Earning ratio at F. This means that BNTC stock's Price/Earning ratio is above 84% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this BNTC may be a overvalued for its sector.
The last closing price of BNTC's stock was USD 10.00.
The most recent market capitalization for BNTC is USD 0.22B.
Based on targets from 3 analysts, the average taret price for BNTC is projected at USD 15.20 over the next 12 months.
This means that BNTC's stock price may go up by +52.00% over the next 12 months.
We can't find any ETFs which contains Benitec Biopharma Ltd ADR's stock.
As per our most recent records Benitec Biopharma Ltd ADR has 16 Employees.
Benitec Biopharma Ltd ADR's registered address is 3940 Trust Way, Hayward, CA, United States, 94545.
You can get more information about it from Benitec Biopharma Ltd ADR's website at https://benitec.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNTC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
